- Recombinant proteins developed for an array of dreaded infectious diseases encompassing prophylactics and therapeutics.
- The platform technology can be used for the development of number of products.
- Does not require highly contained manufacturing infrastructure (BSL-3 and beyond).
- Campaign-based production possible for each of the platform technology enabling capacity utilization and economies of scale.
- All products developed in compliance with ICH Q series and specific CTD modules.
- Each of the candidate developed would have an FTO or novelty with appropriate IP.
- BioGrit Technologies has expertise across different domains as shown below in Figure 10.
Functions | Description |
Research & Development |
|
Preclinical studies |
|
Clinical Trials |
|
Strategic Regulatory Affairs |
|
Global Business Development and Strategy |
|
Intellectual Property &
Legal compliance |
|
Medical Affairs |
|
BioGRIT Technologies Inc. is a biotechnology startup incepted in 2022 and incubated at the prestigious Toronto Business Development Centre in Ontario, the economic heart of Canada, with its primary focus being research and development of new cutting-edge solutions to tackle infectious diseases.
Our dedicated team fervently works toward the discovery and development of diagnostics, prophylactics, and therapeutics against infectious diseases.